TITLE

Treatment of pancreatic carcinoma by adenoviral mediated gene transfer of vasostatin in mice

AUTHOR(S)
Li, L.; Yuan, Y.-Z.; Lu, J.; Xia, L.; Zhu, Y.; Zhang, Y.-P.; Qiao, M-M.
PUB. DATE
February 2006
SOURCE
Gut;Feb2006, Vol. 55 Issue 2, p259
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Tumour growth is angiogenesis dependent and antiangiogenesis therapy may represent a promising therapeutic option. Aims: To evaluate the inhibitory effect of vasostotin gene mediated by a replication deficient recombinant adenovirus (Ad) on human pancreatic cancer in vivo and to investigate the mechanism of action of vasostotin. Methods: Human umbilical vein endothelium derived ECV304 cells were infected with Ad-vasostatin and Ad-lacZ, and compared with phosphate buffered saline (PBS). MTT (3,-[4,5-dimethylthiozol-2-yl]-2,5- diphenyltetrazolium bromide) assay was used to estimate the proliferation of ECV304 cells; tube formation assay and choriallantoic membrane assay were used to evaluate angiogenesis in vivo and in vitro. Xenografted nude mice with pancreatic cancer were established to observe in vivo tumour growth suppression. Microvessel density revealed by CD31 immunohistochemical staining was measured. Results: Growth and tube formation of ECV304 cells infected with Ad-vasostotin were suppressed significantly compared with cells infected with Ad-lacZ or cells treated with PBS. Neavoscularisofion in the Ad-vasostatin group was less than that in the PBS and Ad-lacZ groups, based on chorioallantoic membrane results. Volumes of pancreatic tumours in the Ad-vasostotin group were significantly smaller than those in the PBS and Ad-lacZ groups at the end of the treatment period. Microvessel density in the Ad- vasostotin group was significantly lower than that in the Ad-lacZ and PBS groups. Conclusion: The vasostatin gene mediated by odenovirus is efficient for gene therapy for pancreatic carcinoma. Suppression of vasostatin on proliferation of vascular endothelium cells and angiogenesis may account for its effect.
ACCESSION #
19552437

 

Related Articles

  • Development and application of adenoviral vectors for gene therapy of cancer. Zhang, Wei-Wei // Cancer Gene Therapy;Mar1999, Vol. 6 Issue 2, p113 

    For successful gene vaccination and therapy of cancer, it is essential to develop gene delivery vectors that can meet clinical and social requirements. The need for improved vectors was clearly manifested during the peak of the first wave of gene therapy. Adenoviral (Ad) vectors have recently...

  • Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Kirn, D // Gene Therapy;Jan2001, Vol. 8 Issue 2, p89 

    Replication-selective microbial agents hold promise as a novel cancer treatment platform. dl1520 (Onyx-015), an E1B-55 kD gene-deleted adenovirus, was the first such genetically engineered agent to be tested in humans. Over 200 cancer patients have been treated to date on over 10 clinical trials...

  • Complementary adenoviral vectors for oncolysis. Alemany, Ramon; Lai, Shoupeng; Lou, Yan Chun; Jan, Hsing-Yi; Fang, Xiangming; Zhang, Wei-Wei // Cancer Gene Therapy;Jan1999, Vol. 6 Issue 1, p21 

    Replication-competent adenoviruses (Ads) were used for oncolytic virotherapy soon after they were discovered. Recently mutated and genetically engineered Ads have been shown to selectively lyse tumor cells. We have split the human Ad type 5 genome into two defective viruses that complement each...

  • Oncolytic replication-competent adenovirus suppresses tumor angiogenesis through preserved E1A region. Saito, Y; Sunamura, M; Motoi, F; Abe, H; Egawa, S; Duda, D. G.; Hoshida, T; Fukuyama, S; Hamada, H; Matsuno, S // Cancer Gene Therapy;Mar2006, Vol. 13 Issue 3, p242 

    An adenovirus (Adv) retaining normal E1A but lacking the 55 kDa E1B protein replicates preferentially in TP53-deficient cancer cells including pancreatic cancer cell lines, resulting in the oncolysis of the tumor. When tumor cells are exposed to hypoxia, hypoxia-inducible factor-1α...

  • Antiangiogenic Gene Therapy in Cancer. Zhang, L.; Chen, Q.R.; Mixson, A.J. // Current Genomics;Sep2000, Vol. 1 Issue 2, p117 

    One of the most recent and exciting approaches in cancer gene therapy is the ability to target the developing blood supply of the tumor. An appealing feature of antiangiogenic gene therapy is that the tumor vasculature is a readily accessible target, particularly when the carrier and its gene...

  • Derivation of a Triple Mosaic Adenovirus for Cancer Gene Therapy. Yizhe Tang; Hongju Wu; Ugai, Hideyo; Matthews, Qiana L.; Curiel, David T. // PLoS ONE;2009, Vol. 4 Issue 12, p1 

    A safe and efficacious cancer medicine is necessary due to the increasing population of cancer patients whose particular diseases cannot be cured by the currently available treatment. Adenoviral (Ad) vectors represent a promising therapeutic medicine for human cancer therapy. However, several...

  • A Hypoxia-Regulated Adeno-Associated Virus Vector for Cancer-Specific Gene Therapy. Ruan, Hangjun; Su, Hua; Hu, Lily; Lamborn, Kathleen R; Kan, Y W; Deen, Dennis F // Neoplasia;May2001, Vol. 3 Issue 3, p255 

    The presence of hypoxic cells in human brain tumors is an important factor leading to resistance to radiation therapy. However, this physiological difference between normal tissues and tumors also provides the potential for designing cancer-specific gene therapy. We compared the increase of gene...

  • A Novel TARP-Promoter-Based Adenovirus against Hormone-Dependent and Hormone-Refractory Prostate Cancer. Cheng, Wing-Shing; Kraaij, Robert; Nilsson, Berith; van der Weel, Laura; de Ridder, Corrina M.A.; Tötterman, Thomas H.; Essand, Magnus // Molecular Therapy;Aug2004, Vol. 10 Issue 2, p355 

    TARP (T cell receptor γ-chain alternate reading frame protein) is a protein that in males is uniquely expressed in prostate epithelial cells and prostate cancer cells. We have previously shown that the transcriptional activity of a chimeric sequence comprising the TARP promoter (TARPp) and...

  • Tumor-specific gene therapy for uterine cervical cancer using MN/CA9-directed replication-competent adenovirus. Ho Yeong Lim; Miwon Ahn; Hyun Cheol Chung; Gardner, Thomas A.; Chinghai Kao; Sang-Jin Lee; Se Joong Kim // Cancer Gene Therapy;Aug2004, Vol. 11 Issue 8, p532 

    Although gene therapies using tissue-specific promoters have been reported to be a promising tool for treating cancers, few studies have explored this possibility for uterine cervical cancer. MN/CA9 is a transmembrane glycoprotein that was first identified in the human cervical carcinoma cell...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics